Altamira Therapeutics Ltd. (CYTOF) stock
Close on Oct 19, 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Dec 31, 2024
Valuation
- Market cap
- –
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Diluted shares
- 0M
Trading
- Previous close
- $0.09
- Open
- $0.09
- Day's range
- $0.09 – $0.09
- Volume
- 0
- Average volume (20 days)
- 9,126
Valuation needs the share price. It fills in once daily prices are connected and converted from CHF.
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | CYTOF | S&P 500 | Difference | CYTOF per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +1.7% | +0.6% | +1.1 pts | ||
| 3 months | +50.0% | +3.4% | +46.6 pts | ||
| Year to date | -2.7% | +13.3% | −16.0 pts | ||
| 1 year | -9.0% | +16.6% | −25.6 pts | ||
| 3 years | -97.2% | +86.4% | −183.5 pts | -69.5% | +23.1% |
| 5 years | -100.0% | +81.9% | −181.8 pts | -83.3% | +12.7% |
| 10 years | -100.0% | +318.9% | −418.9 pts | -75.1% | +15.4% |
Eleven years at a glance
Fiscal years 2014 to 2024, CHF
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Altamira Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Altamira Therapeutics
Pharmaceutical Preparations
Altamira Therapeutics Ltd. is a preclinical-stage biopharmaceutical company focused on developing ribonucleic acid delivery technology. The company develops peptide-based nanoparticle platforms, notably xPhore along with OligoPhore, SemaPhore, and CycloPhore, designed for intracellular nucleotide delivery. Its investigational pipeline includes preclinical drug candidates such as AM-401 and AM-411, alongside legacy programs including the Bentrio nasal spray and the AM-125 vertigo treatment. Altamira primarily serves and engages with commercial partners, pharmaceutical collaborators, and prospective licensees across the biopharmaceutical industry.
Company profile, executives and historyAltamira Therapeutics stock: common questions
What is Altamira Therapeutics's stock price?
CYTOF closed at $0.09 on Oct 19, 2026, up 0.00% on the day.
Does Altamira Therapeutics pay a dividend?
No. Altamira Therapeutics has not paid a cash dividend over the last twelve months.
How has CYTOF stock performed over the past year?
Including dividends, CYTOF returned -9.0% over the past year, against +16.6% for the S&P 500.
Who are Altamira Therapeutics's competitors?
Companies most similar to Altamira Therapeutics by business, industry and size include SER, PRQR, LRMR, TRDA, TLSA.
See a number that looks wrong?